Medical Director of Innovative Cancer Therapeutics
Associate Professor of Pediatric Hematology/Oncology
Medical School: University of Texas Southwestern Medical School at Dallas, 2004-2008
Residency: Pediatrics, University of Arkansas of Medical Sciences/Arkansas Children’s Hospital, 2008-2011
Fellowship: Pediatric Hematology/Oncology and Neuro-Oncology, Baylor College of Medicine, 2012-2016
Certifications: American Board of Pediatrics (2011), American Board of Pediatric Hematology/Oncology (2017)
Track: Clinician Educator, Tenure
Interests:
Dr. Bielamowicz’s clinical interests include clinical trials for disease groups such as pediatric brain and spinal cord tumors, neurofibromatosis, cancer predisposition syndromes, neuroblastoma, retinoblastoma, and histiocytic diseases.
Research:
Dr. Bielamowicz is involved in clinical trial design and implementation through several national and international consortia including the Beat Childhood Cancer Consortium (BCC), the Pediatric Oncology Experimental Therapeutics Investigators Consortium (POETIC), and the North American Consortium for Histiocytosis (NACHO). He is the PI for our blood and cancer disorders biorepository.
Leadership Roles:
Medical Director, Brain Tumor Clinic
Medical Director, Cancer Predisposition Clinic
Medical Director, Innovative Cancer Therapeutics Program